Company: Inflarx N. V.
Job title: Vice President, Program Head Dermatology & Oncology
A New Role of Complement C5a Signalling in Immunodermatology: First Results from a Dose-Escalation Study in Pyoderma Gangreanosum 12:00 pm
Discussing InflaRx approach linking Complement signaling with treatments in Immunodermatology Rationale behind C5a inhibition for Pyoderma Gangraenosum Promising results from a dose-escalation study for vilobelimab, a first-in-class monoclonal antibody targeting C5aRead more
day: Day Two